CytomX Therapeutics, Inc.CTMXEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CTMX Q3 2025 Key Financial Metrics
Revenue
$6.0M
Gross Profit
N/A
Operating Profit
$-15.8M
Net Profit
$-14.2M
Gross Margin
N/A
Operating Margin
-264.4%
Net Margin
-238.6%
YoY Growth
-82.2%
Financial Flow
CytomX Therapeutics, Inc. Q3 2025 Financial Summary
CytomX Therapeutics, Inc. reported revenue of $6.0M for Q3 2025, with a net profit of $-14.2M (-238.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $6.0M |
|---|---|
| Net Profit | $-14.2M |
| Gross Margin | N/A |
| Operating Margin | -264.4% |
| Report Period | Q3 2025 |
CytomX Therapeutics, Inc. Annual Revenue by Year
CytomX Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $138.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $138.1M |
| 2023 | $101.2M |
| 2022 | $53.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.6M | $41.5M | $25.1M | $33.4M | $38.1M | $50.9M | $18.7M | $6.0M |
| YoY Growth | 2709.6% | 76.4% | 1.6% | 26.7% | 43.2% | 22.8% | -25.7% | -82.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $201.8M | $184.7M | $159.2M | $139.0M | $120.5M | $98.5M | $175.1M | $158.3M |
| Liabilities | $249.2M | $216.4M | $190.4M | $162.4M | $121.0M | $73.4M | $55.1M | $50.9M |
| Equity | $-47.4M | $-31.7M | $-31.2M | $-23.5M | $-456000 | $25.0M | $119.9M | $107.4M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.0M | $-26.0M | $-19.5M | $-20.7M | $-19.9M | $-21.0M | $-15.8M | $-15.5M |